Rocket Pharmaceuticals details FDA-aligned pivotal Phase 2 trial strategy for RP-A501 gene therapy targeting Danon disease.

Observed price moves

• RCKT+2.44%10 min after this headline

MoveSurge carries market-moving headlines the moment they reach the wire, each one with what the price did next.